DE60135732D1 - Topoisomerasehemmern zur behandlung von chirurgischen verklebungen - Google Patents

Topoisomerasehemmern zur behandlung von chirurgischen verklebungen

Info

Publication number
DE60135732D1
DE60135732D1 DE60135732T DE60135732T DE60135732D1 DE 60135732 D1 DE60135732 D1 DE 60135732D1 DE 60135732 T DE60135732 T DE 60135732T DE 60135732 T DE60135732 T DE 60135732T DE 60135732 D1 DE60135732 D1 DE 60135732D1
Authority
DE
Germany
Prior art keywords
topoisomerase inhibitors
treatment
surgical applications
restonosis
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60135732T
Other languages
English (en)
Inventor
John K Jackson
Helen M Burt
Stephen K Dordunoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of DE60135732D1 publication Critical patent/DE60135732D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60135732T 2000-02-28 2001-02-28 Topoisomerasehemmern zur behandlung von chirurgischen verklebungen Expired - Fee Related DE60135732D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18556500P 2000-02-28 2000-02-28
PCT/CA2001/000247 WO2001064214A2 (en) 2000-02-28 2001-02-28 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors

Publications (1)

Publication Number Publication Date
DE60135732D1 true DE60135732D1 (de) 2008-10-23

Family

ID=22681523

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60135732T Expired - Fee Related DE60135732D1 (de) 2000-02-28 2001-02-28 Topoisomerasehemmern zur behandlung von chirurgischen verklebungen

Country Status (7)

Country Link
US (1) US8883856B2 (de)
EP (2) EP2000136A3 (de)
JP (1) JP2003525243A (de)
AT (1) ATE407676T1 (de)
CA (1) CA2401340A1 (de)
DE (1) DE60135732D1 (de)
WO (1) WO2001064214A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002045D0 (sv) * 2000-05-31 2000-05-31 Sahltech Ab New use
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7074824B2 (en) 2001-07-31 2006-07-11 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US6962944B2 (en) 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US8450071B2 (en) 2002-03-08 2013-05-28 The Board Of Regents Of The University Of Oklahoma Biomarker and method for detecting a chronic inflammatory-associated disease
US7655480B2 (en) * 2002-03-08 2010-02-02 The Board Of Regents Of The University Of Oklahoma Method for predicting sepsis or an acute infectious inflammatory response
AU2003220034A1 (en) * 2002-03-08 2003-09-22 Heloise, Anne, Pereira, Ph. D. An early detection marker for chronic inflammatory associated diseases
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
AR039729A1 (es) * 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
DE10234398B4 (de) * 2002-07-23 2006-07-27 Ls-Medcap Gmbh Beschichtungszusammensetzung für eine implantierbare medizinische Vorrichtung und Verfahren zur Beschichtung einer solchen Vorrichtung und seine Verwendung
US20050208101A1 (en) * 2002-07-23 2005-09-22 Viktor Sevastianov Coating composition for an implantable medical device and method for coating such a device
BR0314743A (pt) * 2002-09-26 2005-07-26 Angiotech Int Ag Envoltórios perivasculares
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US7649013B2 (en) * 2003-11-26 2010-01-19 Arqule, Inc. Methods of protecting against radiation injury
WO2005060951A2 (en) * 2003-12-19 2005-07-07 Bionaut Pharmaceuticals, Inc. Anti-neoplastic agents, combination therapies and related methods
US8828416B2 (en) * 2004-03-09 2014-09-09 Cordis Corporation Local vascular delivery of topotecan in combination with rapamycin to prevent restenosis following vascular injury
WO2005089800A1 (ja) * 2004-03-17 2005-09-29 Locomogene, Inc. hsHRD3を含む医薬組成物
JP2007532885A (ja) * 2004-04-09 2007-11-15 ユニバーシティ オブ ピッツバーグ 急性炎症状態を検出するリアルタイム方法
CN1788310B (zh) * 2004-04-27 2010-06-16 柯尼卡美能达精密光学株式会社 物镜及光拾取装置
US20060135442A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
US20070105790A1 (en) * 2004-09-02 2007-05-10 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
EP1789090A2 (de) * 2004-09-02 2007-05-30 Bionaut Pharmaceuticals, Inc. Kombinatorische chemotherapiebehandlung mit na+/k+-atpase-hemmern
US20060135468A1 (en) * 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
WO2006063430A1 (en) * 2004-12-16 2006-06-22 Miv Therapeutics Inc. Multi-layer drug delivery device and method of manufacturing same
KR100752244B1 (ko) * 2005-02-16 2007-08-27 주식회사 엠디바이오알파 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 약제 조성물
CN105879114A (zh) * 2005-02-18 2016-08-24 阿布拉西斯生物科学公司 用于整合入医疗装置的疏水性改善的药物
EP1871353B1 (de) * 2005-04-15 2010-12-22 ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, a division of YESHIVA UNIVERSITY Vitamin k zur vorbeugung und behandlung von hautausschlag infolge einer anti-egfr-therapie
US20060275341A1 (en) * 2005-06-02 2006-12-07 Miv Therapeutics Inc. Thin foam coating comprising discrete, closed-cell capsules
US20110076278A1 (en) * 2005-08-02 2011-03-31 Mehran Khodadoust Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders
CA2656613A1 (en) * 2006-07-03 2008-01-10 Genmab A/S Prevention of rash in patients undergoing anti-egfr therapy
US20080051702A1 (en) * 2006-08-24 2008-02-28 Herrmann Robert A Therapeutic agent delivery for the treatment of asthma via implantable and insertable medical devices
KR20080047956A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 발기부전의 치료 및 예방을 위한 약제 조성물
US9399675B2 (en) 2007-02-28 2016-07-26 The Board Of Regents Of The University Of Oklahoma Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
US20120100218A1 (en) * 2008-01-30 2012-04-26 Laird Forrest Intralymphatic Chemotherapy Drug Carriers
CA2755014A1 (en) 2008-03-10 2009-09-17 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
US8858995B2 (en) 2008-03-10 2014-10-14 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
US8815953B2 (en) 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
EP2347259A4 (de) * 2008-10-16 2012-02-29 Cypress Bioscience Inc Verfahren zur diagnose und überwachung der krankheitsaktivität und reaktion auf die behandlung bei systemischem lupus erythematodes (sle) und anderen autoimmunerkrankungen
EP2395982B1 (de) * 2008-12-23 2014-10-22 Surmodics Pharmaceuticals, Inc. Implantierbares kompositmaterial enthaltend einen klebrigen biokompatiblen polymerfilm und ein freisetzbares biologisch wirksames mittel
US8940705B2 (en) * 2009-01-09 2015-01-27 The Regents Of The University Of California Method of treating disease and selectively modulating transcriptional regulation by a glucocorticoid receptor by administering aclacinomycin and dexamethasone
CA2773552C (en) * 2009-09-15 2017-11-21 Csl Limited Treatment of neurological conditions
WO2011057286A1 (en) * 2009-11-09 2011-05-12 Drexel University Compositions and methods for treating a disorder or defect in soft tissue
US20120142650A1 (en) * 2010-12-07 2012-06-07 John Hollingsworth Method for treating lung disease
ES2622153T3 (es) * 2011-09-08 2017-07-05 Instituto De Medicina Molecular Una antraciclina para el tratamiento de la sepsis
US8877808B2 (en) * 2012-12-06 2014-11-04 Aurin Biotech Inc. Protection against skin diseases by aurin tricarboxylic acid and its derivatives
HRP20231453T1 (hr) 2015-11-16 2024-03-01 Medincell S.A. Postupak za morseliranje i/ili usmjeravanje farmaceutski aktivnih sastojaka na sinovijalno tkivo
US11173154B2 (en) 2015-12-15 2021-11-16 Icahn School Of Medicine At Mount Sinai Methods of treating exacerbated inflammatory response with topoisomerase I inhibitors
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
EP3630188B1 (de) 2017-05-31 2021-08-25 Amplio Pharma AB Pharmazeutische zusammensetzung mit einer kombination von methotrexat und novobiocin und verwendung der zusammensetzung in der therapie
EP3651750A4 (de) * 2017-07-14 2021-04-14 University of Massachusetts Verfahren und zusammensetzungen zur behandlung von entzündungen
EP3698808A4 (de) * 2017-10-20 2021-07-14 Hyogo College Of Medicine Anti-il-6 rezeptorantikörper enthaltende medizinische zusammensetzung zur verhinderung von postoperativer adhäsion
WO2022159730A1 (en) * 2021-01-22 2022-07-28 Icahn School Of Medicine At Mount Sinai Methods of treating lung inflammation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4114238B1 (de) * 1964-09-02 1966-08-09
DE2240187A1 (de) * 1972-08-16 1974-02-21 Jereb Franz Dr Albin Salbe
US4758587A (en) * 1987-03-09 1988-07-19 Syntex (U.S.A.) Inc. Naphthalene anti-psoriatic agents
ATE194283T1 (de) * 1991-02-04 2000-07-15 Ks Biomedix Ltd Naphtochinonderivate zur behandlung von chronischen entzündungen
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
NZ511762A (en) * 1993-07-19 2003-09-26 Univ British Columbia Anti-angiogenic compositions and methods of use
FR2725990B1 (fr) * 1994-10-21 1997-01-10 Pf Medicament Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US5736129A (en) * 1995-11-17 1998-04-07 Medenica; Rajko D. Flow cytometric pharmacosensitivity assay and method of cancer treatment
US5847003A (en) * 1996-06-04 1998-12-08 Avon Products, Inc. Oxa acids and related compounds for treating skin conditions
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
EP0990635B1 (de) * 1997-06-13 2003-09-17 Takara Bio Inc. Hydroxycyclopentanone
US6485514B1 (en) * 1997-12-12 2002-11-26 Supergen, Inc. Local delivery of therapeutic agents
EP1085859A4 (de) * 1998-06-11 2003-02-26 Univ New Jersey Med Wundbehandlung zur hemmung der adenosinetriphosphoteribosyltransferase
JP2002519335A (ja) * 1998-06-26 2002-07-02 クアナム メディカル コーポレイション 再狭窄の予防のためのトポイソメラーゼインヒビター
AU1678900A (en) * 1998-08-11 2000-03-06 All India Institute Of Medical Sciences A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
US6281223B1 (en) 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
US6187822B1 (en) 1999-06-11 2001-02-13 University Of Medicine & Dentistry Of Nj Wound treatment through inhibition of adenosine diphosphate ribosyl transferase
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin

Also Published As

Publication number Publication date
EP1261337A2 (de) 2002-12-04
EP2000136A3 (de) 2008-12-31
CA2401340A1 (en) 2001-09-07
JP2003525243A (ja) 2003-08-26
WO2001064214A2 (en) 2001-09-07
WO2001064214A3 (en) 2002-05-10
US20030139353A1 (en) 2003-07-24
EP1261337B1 (de) 2008-09-10
ATE407676T1 (de) 2008-09-15
US8883856B2 (en) 2014-11-11
EP2000136A2 (de) 2008-12-10

Similar Documents

Publication Publication Date Title
DE60135732D1 (de) Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE554756T1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
DK1420801T3 (da) Anvendelse af fucaner til behandling af adhæsioner, arthritis og psoreasis
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
DE60035378D1 (de) Gerät zur Behandlung von Bandscheiben
ATE542801T1 (de) Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
DE60043075D1 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE323693T1 (de) Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen
DK1313740T3 (da) Prodrugs af imidazopyridinderivater
SE0302304D0 (sv) Novel compounds
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
ATE418552T1 (de) Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
SE0003476D0 (sv) Compounds
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
TR200200278T2 (tr) Kalsilitik bileşimler
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee